<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04793529</url>
  </required_header>
  <id_info>
    <org_study_id>RC-2-3-2021</org_study_id>
    <nct_id>NCT04793529</nct_id>
  </id_info>
  <brief_title>Is Involucrin Has a Role in Verruca Vulgaris? A Clinical and Immunohistochemical Study</brief_title>
  <official_title>Is Involucrin Has a Role in Verruca Vulgaris? A Clinical and Immunohistochemical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Benha University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Benha University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vitamin D3 plays important role in keratinocyte differentiation and had been used recently in&#xD;
      verruca vulgaris. Aim of the work: To assess the expression of involucrin in verrucae&#xD;
      vulgaris before and after injection of vitamin D3. Subjects and Methods: This study included&#xD;
      60 patients with verrucae vulgaris subjected to intralesional injection of vitamin D3 at&#xD;
      three weeks interval for a maximum of five sessions. Immunohistochemical assessment of&#xD;
      involucrin was done before and after injection and compared to skin biopsies from 30 healthy&#xD;
      individuals&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Actual">October 1, 2019</completion_date>
  <primary_completion_date type="Actual">October 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Resolution of verrucae</measure>
    <time_frame>3 months</time_frame>
    <description>Decrease of verrucae size Decrease of verrucae number</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Involucrin expression</measure>
    <time_frame>3 months</time_frame>
    <description>Change of expression pattern of involucrin by immunohistochemical study Change of expression grade of involucrin by immunohistochemical study</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Verruca Vulgaris</condition>
  <condition>Involucrin</condition>
  <arm_group>
    <arm_group_label>Cholecalciferol injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cholecalciferol</intervention_name>
    <description>Cholecalciferol injection</description>
    <arm_group_label>Cholecalciferol injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
        Patients with multiple verruca vulgaris Patients with with verrucae vulgaris with size more&#xD;
        than 3 cm&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients with a past history of allergic response to vitamin D. Pregnant or lactating&#xD;
        females. Hepatic patients. Renal patients. Patients with bleeding tendency.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Essam Mohamed El-sayed Akl</name>
      <address>
        <city>BanhƒÅ</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 4, 2021</study_first_submitted>
  <study_first_submitted_qc>March 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 11, 2021</study_first_posted>
  <last_update_submitted>March 9, 2021</last_update_submitted>
  <last_update_submitted_qc>March 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Benha University</investigator_affiliation>
    <investigator_full_name>Essam Mohamed El-sayed Akl</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warts</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

